Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$649000.0.

  • Cardiff Oncology's Net Cash Flow rose 9479.26% to -$649000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 3225.51%. This contributed to the annual value of $29.8 million for FY2024, which is 46169.93% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Net Cash Flow is -$649000.0, which was up 9479.26% from -$13.3 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Net Cash Flow peaked at $38.4 million during Q4 2024, and registered a low of -$116.3 million during Q1 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$1.3 million (2023), whereas its average is -$6.4 million.
  • In the last 5 years, Cardiff Oncology's Net Cash Flow tumbled by 1257091.5% in 2021 and then skyrocketed by 49844.29% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Net Cash Flow stood at -$1.2 million in 2021, then plummeted by 93.94% to -$2.4 million in 2022, then skyrocketed by 370.97% to $6.4 million in 2023, then soared by 498.44% to $38.4 million in 2024, then plummeted by 101.69% to -$649000.0 in 2025.
  • Its Net Cash Flow was -$649000.0 in Q3 2025, compared to -$13.3 million in Q2 2025 and -$27.4 million in Q1 2025.